NVO
Novo Nordisk A/S
NVO has the edge over TFX overall, supported by stronger modeled upside and stronger valuation.
TFX
Teleflex Incorporated
TFX trails on the overall score without a compensating advantage in the available component scores.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
TFX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Healthy | |
| Under pressure | |
| Under pressure |
TFX's profitability is currently healthy, but its revenue, cash flow and balance sheet are under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
TFX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 15x | $153 | — |
| Current | 19x | $153 | — |
| Cheap | 28x | $227 | +48% |
| Fair | 34x | $279 | +82% |
| Expensive | 49x | $404 | +164% |
Historical ranges are pointers, not guarantees.
TFX has the edge over NVO in the historical PE scenario, which offers more potential upside but is not a forecast.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
TFX Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Decline | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect TFX's earnings to grow and its profitability to improve, but its revenue to decline.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over TFX on earnings, with more consistent year-over-year improvement.
TFX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.93 | +21% |
| Q3 2026 | $8.23 | +$15.52 |
| Q2 2026 | -$23.29 | -640% |
| Q1 2026 | -$22.80 | -806% |
| Q4 2025 | -$20.55 | -1489% |
| Q3 2025 | -$7.29 | -245% |
| Q2 2025 | $4.31 | -23% |
| Q1 2025 | $3.23 | -48% |
| Q4 2024 | $1.48 | -80% |
TFX has returned to profit: it earned $8.23 per share over the past year, after losing money the year before. Its recent earnings include one-off gains.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over TFX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over TFX on profitability, with a higher operating margin.
TFX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $567.8M | -38% |
| Q2 2026 | $570.3M | -27% |
| Q1 2026 | $548.3M | -22% |
| Q4 2025 | $569M | -28% |
| Q3 2025 | $913M | +19% |
| Q2 2025 | $780.9M | +4.2% |
| Q1 2025 | $700.7M | -5% |
| Q4 2024 | $795.4M | +2.8% |
TFX's revenue has slid since its 2025 peak: $568M last quarter, down 38% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +63 points |
| Q2 2026 | 13% | -7.1 points |
| Q1 2026 | 3.7% | -14 points |
| Q4 2025 | 2.4% | +16 points |
| Q3 2025 | -45% | -64 points |
| Q2 2025 | 20% | +4.3 points |
| Q1 2025 | 18% | +19 points |
| Q4 2024 | -14% | -25 points |
TFX's operating margin was 19% last quarter, up 63 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over TFX on cash flow, with more consistent year-over-year improvement.
TFX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $74.7M | -4.1% |
| Q2 2026 | $77.9M | +$104.6M |
| Q1 2026 | $27.9M | -36% |
| Q4 2025 | -$92.9M | -154% |
| Q3 2025 | $77.8M | -63% |
| Q2 2025 | -$26.8M | -147% |
| Q1 2025 | $43.3M | -42% |
| Q4 2024 | $170.6M | +53% |
TFX still generates free cash flow, though less than at its 2024 peak: $87M over the past year.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
TFX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4.7% | -2M shares |
| 1 year | -5.9% | -2.6M shares |
| 3 years | -12% | -5.7M shares |
| 5 years | -12% | -5.8M shares |
| Available history | -12% | -5.5M shares |
TFX has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $305M |
| Q2 2026 | $250M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $300M |
| Q4 2024 | — |
TFX spent $555M buying back its own shares over the past year, up 85% from the year before.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over TFX on leverage, with a lower net debt burden relative to earnings.
TFX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.6x | Elevated |
| Q4 2025 | 35.6x | High |
| Q3 2025 | 52.2x | High |
| Q2 2025 | 2.8x | Moderate |
| Q1 2025 | 2.9x | Moderate |
| Q4 2024 | 3.2x | Elevated |
| Q3 2024 | 2.5x | Moderate |
| Q2 2024 | 2.4x | Moderate |
TFX's net debt is about 3.6 years of its operating earnings (EBITDA), up from 2.9 years a year ago.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
TFX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.4 | Neutral |
| Stochastic | 85.3 | Overbought |
TFX's weekly RSI is 68 (neutral) and its Stochastic is 85 (overbought).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over TFX on valuation relative to its sector.
TFX PE vs Healthcare Sector
| Metric | TFX | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 26x | 28% below |
| PE % | 1 | 29 | 28 pts below |
TFX is trading at 19x earnings, a 28% discount to the Healthcare sector's median of 26x, though its recent earnings include one-off gains.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
TFX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $135.2 | 13% above |
| 20 week MA | $135.0 | 13% above |
| 50 week MA | $125.9 | 22% above |
| 100 week MA | $130.4 | 17% above |
| 200 week MA | $179.2 | 15% below |
TFX has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
TFX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $372.0 | $405.1 | +8.9% |
| 2021 | $405.1 | $327.4 | -19% |
| 2022 | $327.4 | $248.8 | -24% |
| 2023 | $248.8 | $249.3 | +0.2% |
| 2024 | $249.3 | $179.5 | -28% |
| 2025 | $179.5 | $122.8 | -32% |
| 2026 YTD | $122.8 | $153.2 | +25% |
TFX has the edge over NVO on returns for 2026, with the stronger performance.